The comparison between BPC-157 and TB-500 represents a fundamental exercise in peptide biochemistry. These two molecules, while often discussed together in research literature, differ significantly in their amino acid composition, molecular weight, structural characteristics, and biochemical origin. This page provides a detailed educational comparison of their molecular profiles.
1.BPC-157 And TB-500 Amino Acid Sequence Comparison
BPC-157 is a pentadecapeptide—a chain of 15 amino acids—first identified in human gastric juice. Its complete sequence reads: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, abbreviated as GEPPPGKPADDAGLV. The peptide is notable for its high proline content (three consecutive proline residues at positions 3-5), which contributes to its
TB-500, by contrast, is a synthetic analog of Thymosin Beta-4, a 43-amino acid peptide. The full sequence of Thymosin Beta-4 is Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES. The TB-500 designation typically refers to the full-length synthetic peptide or its key active fragment containing the LKKTETQ motif (residues 17-23), which has been identified as a primary actin-binding domain in laboratory studies.
| Parameter | BPC-157 | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Classification | Pentadecapeptide | Peptide (43 aa) |
| Amino Acid Count | 15 | 43 |
| Sequence Length | Short chain | Medium chain |
| Key Structural Feature | Proline-rich region | LKKTETQ actin-binding motif |
| N-terminal Modification | Free N-terminus | Acetylated (Ac-) |
2.BPC-157 And TB-500 Molecular Weight and Formula
The molecular weight difference between these two peptides is substantial. BPC-157 has a molecular weight of approximately 1,419.55 g/mol, with the molecular formula C62H98N16O22. TB-500, being nearly three times longer in amino acid count, has a molecular weight of approximately 4,963.55 g/mol and the molecular formula C212H350N56O78S. This significant size difference has important implications for laboratory handling, solubility, and formulation chemistry.
The presence of a single methionine residue in TB-500 (containing sulfur) gives it a molecular formula that includes a sulfur atom, whereas BPC-157 contains no sulfur-containing amino acids. This distinction is relevant when considering oxidation sensitivity during laboratory storage and handling.
3.BPC-157 And TB-500 Biochemical Origin and Discovery
BPC-157 was originally isolated from human gastric juice and represents a stable gastric pentadecapeptide. Research into this peptide began in the context of gastrointestinal cytoprotection studies. The peptide is synthesized artificially for research purposes, as extracting sufficient quantities from natural sources is impractical for laboratory work.
TB-500 is a synthetic version of Thymosin Beta-4, which was originally isolated from the thymus gland. Thymosin Beta-4 is a naturally occurring peptide found in nearly all human and animal cells, and it is one of the most abundant intracellular peptides. The synthetic TB-500 used in research is produced through solid-phase peptide synthesis (SPPS) to ensure batch-to-batch consistency and purity.
4.BPC-157 And TB-500 Structural Characteristics
BPC-157's structure is characterized by its compact 15-amino acid chain and the unusual tri-proline sequence. Proline residues introduce conformational rigidity due to their cyclic side chain, which restricts the backbone dihedral angle. This rigidity may influence the peptide's resistance to enzymatic degradation in laboratory conditions.
TB-500's 43-amino acid structure contains multiple charged residues and a well-defined actin-binding region. The LKKTETQ sequence (Leu-Lys-Lys-Thr-Glu-Thr-Gln) is of particular interest in laboratory studies, as this motif is responsible for the peptide's interaction with G-actin monomers. The N-terminal acetylation of the native Thymosin Beta-4 sequence is preserved in synthetic TB-500 preparations.
5.BPC-157 And TB-500 Laboratory Handling Considerations
Due to their different molecular weights and structures, BPC-157 and TB-500 require different handling protocols in laboratory settings. BPC-157, being smaller, typically demonstrates good solubility in aqueous buffers and moderate stability at room temperature. TB-500, with its larger structure and sulfur-containing methionine residue, may require additional considerations for storage stability.
When these peptides are used in research formulations, their different molecular weights must be accounted for in concentration calculations. For example, achieving equivalent molar concentrations requires different mass amounts due to the approximately 3.5-fold difference in molecular weight. Our blend composition page discusses this in greater detail.
6.BPC-157 And TB-500 Research Classification
In biochemical classification, BPC-157 falls under the category of synthetic gastric peptides, while TB-500 is classified as a thymosin analog. Both are categorized as research peptides and are not approved by regulatory agencies for human therapeutic use. Their study in laboratory settings continues to expand our understanding of peptide biochemistry.
For researchers interested in the combination of these two peptides, our stack configuration page provides detailed information about compatibility considerations. For information about different dosage forms available in research, see our dosage forms guide.